ADMA Biologics (NASDAQ:ADMA) Stock Price Down 5.1% - Here's Why

Key Points

• ADMA Biologics stock price decreased by 5.1%, closing at $14.81 after trading as low as $14.83, with a significant drop in trading volume to approximately 1.95 million shares.
• The company reported earnings of $0.15 per share, exceeding analyst estimates, with a 13.8% increase in quarterly revenue compared to the same period last year.
• Institutional ownership of ADMA Biologics stands at 75.68%, with recent investments indicating growing interest from large investors, including stake increases by Cullen Frost Bankers Inc. and Smartleaf Asset Management LLC.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report)'s stock price was down 5.1% during trading on Monday . The company traded as low as $14.83 and last traded at $14.81. Approximately 1,946,360 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 3,139,529 shares. The stock had previously closed at $15.61.

ADMA Biologics Price Performance

The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of 17.09 and a beta of 0.54. The business's fifty day simple moving average is $17.02 and its 200 day simple moving average is $18.89. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period last year, the firm earned $0.13 earnings per share. The business's quarterly revenue was up 13.8% compared to the same quarter last year. On average, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ bought a new position in shares of ADMA Biologics during the first quarter valued at about $35,000. SVB Wealth LLC purchased a new position in shares of ADMA Biologics in the first quarter worth about $35,000. Cullen Frost Bankers Inc. increased its stake in shares of ADMA Biologics by 112.5% in the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 1,081 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of ADMA Biologics by 161.4% in the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,493 shares in the last quarter. Finally, Ameritas Advisory Services LLC purchased a new position in ADMA Biologics during the second quarter valued at approximately $46,000. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.